Hologic Posts 6 Percent Increase in Q4 Revenues Driven Partly by Gen-Probe; Takes $1.11B Impairment Charge | GenomeWeb

NEW YORK (GenomeWeb News) — Hologic reported after the close of the market Monday a 6 percent increase in fiscal fourth quarter revenues, including a 14 percent spike in Diagnostics revenues driven primarily by the inclusion of a full quarter of Gen-Probe's sales.

For the three months ended Sept. 28, Hologic reported revenues of $622.1 million, up from $588.5 million in the same quarter last year, and falling short of the average Wall Street estimate of $624.4 million.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Cell this week: proteomic consequences of genomic changes in ovarian cancer, Human SRMAtlas, and more.

At Nature, John Wilbanks and Eric Topol call for openness in health data.

Law.com predicts that genomic and genetic testing will become common in toxic tort cases.

A Pew Research Center report finds that most Americans are wary of using technologies like gene editing to enhance human abilities.